|
CFCF is pleased to announce that this E-Update is supported by Novartis Pharmaceuticals Corporation |
 Follow us on Twitter!
 Join us on Facebook!
Visit us on Navigating Cancer! |
(submitted 3/22/11)
CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination. Thank you to our Survivors for sharing their courage and words of hope with other patients.
Read our newest survivor stories:
|
|
Join Us for a Cure
Make a difference and get involved with CFCF! Unite, meet fellow members of the carcinoid community, and spread awareness at upcoming CFCF events! |
Give hope and a future to neuroendocrine tumor patients: donate to CFCF where 100% of all individual donations go to carcinoid and related neuroendocrine tumor research. CFCF is a 501(c)(3) organization-all contributions are tax-deductible. We want our donors to know that we are allocating their donations responsibly and wisely to achieve a carcinoid cure as quickly as possible.
To learn more, view CFCF's:
Audited Financial Statements
IRS Form 990
|
CFCF meets all 20 Wise Giving Alliance standards for charity accountability established by the Better Business Bureau. Click here to check out the CFCF Wise Giving Report. |
|
|
|
|
|
|
Two Potential Therapies Closer to FDA Approval
The Oncologic Drugs Advisory Committee (ODAC) of the US Food and Drug Administration (FDA) has recommended the approval of two drugs for use in patients with advanced pancreatic neuroendocrine tumors. Both Afinitor or "RAD001" (everolimus) and Sutent (sunitinib malate) are closer to becoming the first drugs approved to treat pancreatic neuroendocrine tumors since 1982.
Please check out Lauren's blog (see below) or call us at 617.948.2514 for more information on this important development. |
|
Advocating for Patients at FDA Hearings
The Caring for Carcinoid Foundation works to make your voices heard. For the second time in less than a year, CFCF Executive Director Lauren Erb has addressed the FDA on behalf of carcinoid, pancreatic neuroendocrine, and related neuroendocrine cancer patients.
Thank you again to everyone who responded to our survey with their thoughts on everolimus and sunitinib! Your feedback is critical to our mission to find cures for neuroendocrine cancers.
Lauren's most recent blog entry includes her thoughts on sharing your experiences with the Oncologic Drug Advisory Committee (ODAC). Read on to learn how patients were instrumental in the ODAC's recommendations.
|
|
This Fall, Team CFCF Takes on the Windy City
Are you willing to go the extra mile to help find a cure for neuroendocrine cancers? How about the extra 26.2 miles?
For the 5th consecutive year, the Caring for Carcinoid Foundation is fielding a team in the Bank of America Chicago Marathon! Join the 45,000 runners and 1.5 million spectators for one of the premier marathons in the world.
If you would like to run and fundraise as a member of Team CFCF, or volunteer behind the scenes, please send us an e-mail. Check out our website for more information on the event, including photo galleries from past Chicago Marathons. Registration for the race is closed to the public, but CFCF still has charity fundraising spots.
|
|
Study Examines Y-90 Radioactive Microspheres
 New results from a multi-institutional study were presented by researchers at the Society of Interventional Radiology's 36th Annual meeting in support of Y-90 radioactive microspheres to treat liver metastases. The treatment involves the injection of millions of radioactive microspheres (microscopic beads) into the bloodstream to block blood supply to the tumor and kill it using radiation.
The four-year prospective study looked at 151 patients with liver metastases from colorectal, neuroendocrine, and other cancers. The study examined whether higher doses of Y-90 radioactive microspheres can be safe and effective in patients. Current evidence suggests that these higher doses can extend progression-free survival for patients when they are treated in highly skilled and experienced centers. In particular, they may offer hope for patients for whom chemotherapy has failed.
"Now we know that patients can actually tolerate much higher doses of radiation than previously thought, which provides results in patients progressing on standard chemotherapy," noted Riad Salem, MD, MBA, FSIR. "While patients aren't cured, their lives are being extended with less down time and their quality of life is improving."
Read more here. You may also listen to an interview with Dr. Salem and one of his patients for more information on therapy with radioactive microspheres. All patients should discuss any potential treatment or change in care with a physician well-versed in treating patients with neuroendocrine cancer. Please visit CFCF's Doctor Database or call 617.948.2514 for help in finding such a physician.
|
|
|
|
|
